Get ready to dive into a groundbreaking discovery in cancer research! The battle against cancer just got a powerful new weapon. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have unveiled a revolutionary RNA-based therapy that targets a notorious cancer gene, KRAS, while boosting our body's natural immune response. This innovative approach offers a glimmer of hope in the fight against some of the most challenging cancers.
But here's where it gets controversial... KRAS, a molecular switch controlling cell growth, often mutates in cancers like pancreatic, lung, and colorectal, locking it in an 'on' state. This constant activation allows tumors to evade our immune system. Mutations in KRAS are incredibly common, especially in pancreatic cancers, making it a top priority in cancer research.
The research team developed a clever combination therapy using antisense oligonucleotides (ASOs) and immunomodulatory RNA (immRNA) to silence mutant KRAS genes and activate the Retinoic acid-Inducible Gene I (RIG-I) immune pathway, respectively. Think of the RIG-I pathway as our cells' alarm system, alerting our immune system to viral threats.
The team delivered these molecules safely using red blood cell-derived extracellular vesicles (RBCEVs), a natural carrier for nucleic acid drugs. In their first study, published in Theranostics, they demonstrated that this dual treatment killed KRAS-mutant cancer cells, including those from lung, colorectal, and pancreatic cancers, by blocking oncogenic KRAS activity and triggering an immune response.
This dual approach transformed 'cold' tumors, which typically evade immune detection, into 'hot' tumors that our immune system can recognize and attack. Laboratory studies showed reduced tumor burden and extended survival, all without harming healthy cells.
Building on this success, the second study, published in the Journal of Controlled Release, focused on pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC) with peritoneal metastasis. PDAC is an aggressive cancer with a poor prognosis, but the treatment significantly suppressed tumor growth and prolonged survival in laboratory studies. Importantly, safety testing showed no observable toxicity, suggesting a promising path forward for clinical evaluation.
Associate Professor Minh Le, from NUS Medicine, emphasized, "KRAS mutations enable cancer cells to suppress immune responses, leading to metastasis. Our EV platform precisely targets these mutants, synergizing KRAS knockdown with RIG-I activation to unleash a powerful immune response, halting tumor growth and extending survival without toxicity."
Associate Professor Glenn Bonney, from the Division of Hepatobiliary & Pancreatic Surgery, National University Hospital, added, "This dual nucleic acid delivery via biocompatible vesicles offers a safe and scalable approach to treat peritoneal metastasis, a critical unmet need in PDAC."
Professor Dahai Luo from NTU's Lee Kong Chian School of Medicine highlighted the potential of engineering EVs for targeted delivery, turning natural cell messengers into precision weapons against KRAS-addicted cancers like colorectal and lung.
Adjunct Professor Jonathan Loh Yuin-Han from the Institute of Molecular and Cell Biology, A*STAR, emphasized the impact of this innovative combination, stating, "By reprogramming the tumor microenvironment, we're charting a new path toward transforming KRAS-driven cancers and bringing us closer to effective, personalized immunotherapies."
This research not only highlights the potential of extracellular vesicles as safe carriers for nucleic acid therapies but also opens doors to improved treatment outcomes for KRAS-driven malignancies, potentially combined with existing immunotherapies.
And this is the part most people miss... The success of this RNA therapy in silencing the KRAS gene and boosting the immune attack on cancer cells offers a ray of hope in the ongoing battle against cancer. It's a reminder that, with innovative research and collaboration, we can continue to make significant strides in cancer treatment and, ultimately, save lives.
